| 2025-11-21 |
详情>>
内部人交易：
Bitterman Robert J股份增加5000.00股
|
| 2025-11-13 |
详情>>
股本变动：
变动后总股本1076.44万股
|
| 2025-11-13 |
详情>>
业绩披露：
2025年三季报(累计)每股收益-1.3美元,归母净利润-632.7万美元,同比去年增长-14.54%
|
| 2025-08-14 |
详情>>
业绩披露：
2025年中报每股收益-0.86美元,归母净利润-393.5万美元,同比去年增长1.62%
|
| 2025-07-30 |
股东大会：
将于2025-09-11召开股东大会
会议内容 ▼▲
- 1.The election of the six director nominees named in the accompanying Proxy Statement;
2.The ratification of Grant Thornton, LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025;
3.An amendment and restatement of the 2020 Phio Pharmaceuticals Corp. Long Term Incentive Plan to increase the number of shares of common stock available for issuance thereunder by 950,000;
4.An advisory (non-binding) vote to approve the compensation of our named executive officers (commonly referred to as a “Say-on-Pay” vote);
5.An advisory (non-binding) vote to approve the frequency of future advisory votes on the compensation of our named executive officers (commonly referred to as a “Say-on-Frequency” vote);
6.The transaction of any other business that may properly come before the meeting or any adjournment thereof. Pursuant to the Company’s bylaws, no other items of business are expected to be considered at the meeting and no other director nominees will be entertained.
|
| 2025-05-15 |
详情>>
业绩披露：
2025年一季报每股收益-0.41美元,归母净利润-176.9万美元,同比去年增长17.87%
|
| 2025-04-09 |
复牌提示：
2025-04-09 10:19:30 停牌，复牌日期 2025-04-09 10:24:30
|
| 2025-03-31 |
详情>>
业绩披露：
2024年年报每股收益-9.08美元,归母净利润-715万美元,同比去年增长33.96%
|
| 2024-11-14 |
详情>>
业绩披露：
2024年三季报(累计)每股收益-8.23美元,归母净利润-552.4万美元,同比去年增长38.15%
|
| 2024-08-14 |
详情>>
业绩披露：
2024年中报每股收益-7.85美元,归母净利润-400万美元,同比去年增长34.97%
|
| 2024-07-04 |
详情>>
拆分方案：
每9.0000合并分成1.0000股
|
| 2024-05-09 |
详情>>
业绩披露：
2024年一季报每股收益-0.47美元,归母净利润-215.4万美元,同比去年增长40.20%
|
| 2024-05-08 |
股东大会：
将于2024-06-17召开股东大会
会议内容 ▼▲
- 1.The election of the five director nominees named in the accompanying Proxy Statement;
2.The ratification of BDO USA, P.C. as our independent registered public accounting firm for the fiscal year ending December 31, 2024;
3.An amendment to our Amended and Restated Certificate of Incorporation to effect a reverse stock split of the outstanding shares of our common stock, par value $0.0001 per share (the “Common Stock”), at a ratio of not less than 1-for-2 and not greater than 1-for-9, with the exact ratio and effective time of the reverse stock split to be determined by our Board of Directors;
4.An amendment and restatement of the 2020 Phio Pharmaceuticals Corp. Long Term Incentive Plan to increase the number of shares of common stock available for issuance thereunder by 500,000;
5.The transaction of any other business that may properly come before the meeting or any adjournment thereof. Pursuant to the Company’s bylaws, no other items of business are expected to be considered at the meeting and no other director nominees will be entertained.
|
| 2024-04-01 |
详情>>
业绩披露：
2023年年报每股收益-5.2美元,归母净利润-1082.6万美元,同比去年增长5.70%
|
| 2023-11-09 |
详情>>
业绩披露：
2023年三季报(累计)每股收益-5.03美元,归母净利润-893.1万美元,同比去年增长-2.08%
|
| 2023-08-10 |
详情>>
业绩披露：
2023年中报每股收益-4.28美元,归母净利润-615.1万美元,同比去年增长-18.91%
|
| 2023-06-09 |
股东大会：
将于2023-07-20召开股东大会
会议内容 ▼▲
- 1.The election of the five director nominees named in the accompanying Proxy Statement;
2.The ratification of BDO USA, LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2023;
3.An amendment and restatement of the 2020 Phio Pharmaceuticals Corp. Long Term Incentive Plan to increase the number of shares of common stock available for issuance thereunder by 125,500;
4.The transaction of any other business that may properly come before the meeting or any adjournment thereof. Pursuant to the Company’s bylaws, no other items of business are expected to be considered at the meeting and no other director nominees will be entertained.
|
| 2023-01-26 |
详情>>
拆分方案：
每12.0000合并分成1.0000股
|
| 2022-11-30 |
股东大会：
将于2023-01-04召开股东大会
会议内容 ▼▲
- 1.An amendment to our Amended and Restated Certificate of Incorporation to effect a reverse stock split of the outstanding shares of our common stock, par value $0.0001 per share (the “Common Stock”), at a ratio of not less than 1-for-2 and not greater than 1-for-25, with the exact ratio and effective time of the reverse stock split to be determined by our Board of Directors;
2.The transaction of any other business that may properly come before the meeting or any adjournment thereof. Pursuant to our bylaws, no other items of business are expected to be considered at the meeting.
|
| 2022-06-30 |
股东大会：
将于2022-08-09召开股东大会
会议内容 ▼▲
- 1.The election of the six director nominees named in the accompanying Proxy Statement;
2.The ratification of BDO USA, LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2022;
3.An advisory (non-binding) vote to approve the Company’s executive compensation;
4.The transaction of any other business that may properly come before the meeting or any adjournment thereof. Pursuant to the Company’s bylaws, no other items of business are expected to be considered at the meeting and no other director nominees will be entertained.
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-04-30 |
股东大会：
将于2021-06-15召开股东大会
会议内容 ▼▲
- 1.the election of the seven director nominees named in the accompanying Proxy Statement;
2.the ratification of BDO USA, LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2021.
|
| 2020-08-28 |
股东大会：
将于2020-10-08召开股东大会
会议内容 ▼▲
- 1.the election of the seven director nominees named in the accompanying Proxy Statement;
2.the ratification of BDO USA, LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2020;
3.an approval of the 2020 Phio Pharmaceuticals Corp. Long Term Incentive Plan;
4.the transaction of any other business that may properly come before the meeting or any adjournment thereof. Pursuant to the Company’s bylaws, no other items of business are expected to be considered at the meeting and no other director nominees will be entertained.
|
| 2020-01-15 |
详情>>
拆分方案：
每55.0000合并分成1.0000股
|
| 2019-11-22 |
股东大会：
将于2019-12-12召开股东大会
会议内容 ▼▲
- 1.an amendment to the Company’s Amended and Restated Certificate of Incorporation to effect a reverse stock split of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), at a ratio of not less than 1-for-2 and not greater than 1-for-70, with the exact ratio and effective time of the reverse stock split to be determined by the Board of Directors;
2.the transaction of any other business that may properly come before the meeting or any adjournment thereof. Pursuant to the Company’s bylaws, no other items of business are expected to be considered at the meeting.
|
| 2019-08-30 |
股东大会：
将于2019-10-10召开股东大会
会议内容 ▼▲
- 1.the election of the six director nominees named in the accompanying Proxy Statement;
2.the ratification of BDO USA, LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2019;
3.an amendment and restatement of the 2012 Phio Pharmaceuticals Corp. Long Term Incentive Plan to increase the number of shares available for issuance thereunder;
4.an amendment to the Company’s Amended and Restated Certificate of Incorporation to effect a reverse stock split of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), at a ratio of not less than 1-for-2 and not greater than 1-for-20, with the exact ratio and effective time of the reverse stock split to be determined by the Board of Directors;
5.an advisory (non-binding) vote to approve the Company’s executive
6.an advisory (non-binding) vote on the frequency of future votes to approve the Company’s executive compensation;
7.the transaction of any other business that may properly come before the meeting or any adjournment thereof. Pursuant to the Company’s bylaws, no other items of business are expected to be considered at the meeting and no other director nominees will be entertained.
|
| 2018-11-14 |
财报披露：
美东时间 2018-11-14 盘后发布财报
|
| 2018-08-14 |
财报披露：
美东时间 2018-08-14 盘后发布财报
|
| 2018-05-10 |
财报披露：
美东时间 2018-05-10 盘后发布财报
|
| 2018-04-26 |
股东大会：
将于2018-06-05召开股东大会
会议内容 ▼▲
- (1) the election of the six director nominees named in the accompanying Proxy Statement;
(2) the ratification of BDO USA, LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2018;
(3) an approval of the 2012 RXi Pharmaceuticals Corporation Long Term Incentive Plan, as amended, including an increase in the number of shares available for issuance thereunder;
(4) an increase in the number of shares available for issuance under the RXi Pharmaceuticals Corporation Employee Stock Purchase Plan;
(5) an approval, for purposes of complying with Nasdaq Listing Rule 5635(d), of the issuance of more than 20% of the Company’s issued and outstanding common stock pursuant to the Company’s purchase agreement with Lincoln Park Capital Fund, LLC;
(6) the transaction of any other business that may properly come before the meeting or any adjournment thereof. Pursuant to the Company’s bylaws, no other items of business are expected to be considered at the meeting and no other director nominees will be entertained.
|
| 2018-03-26 |
财报披露：
美东时间 2018-03-26 盘后发布财报
|
| 2018-01-05 |
详情>>
拆分方案：
每10.0000合并分成1.0000股
|
| 2017-11-08 |
财报披露：
美东时间 2017-11-08 盘后发布财报
|
| 2017-08-10 |
财报披露：
美东时间 2017-08-10 盘后发布财报
|
| 2017-04-27 |
股东大会：
将于2017-06-06召开股东大会
会议内容 ▼▲
- (1) the election of the five director nominees named in the accompanying Proxy Statement;
(2) the ratification of BDO USA, LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2017;
(3) an amendment to the Company’s Amended and Restated Certificate of Incorporation, as amended, to effect a reverse stock split, if considered by the Board of Directors to be necessary, of the shares of the Company’s common stock, par value $0.0001 per share (the “common stock”), at a ratio of not less than 1-for-2 and not greater than 1-for-40, with the exact ratio and effective time of the reverse stock split to be determined by the Board of Directors;
(4) an approval, for purposes of complying with NASDAQ Listing Rule 5635(d), of the issuance of more than 20% of the Company’s issued and outstanding common stock pursuant to the Company’s acquisition of MirImmune Inc. in January 2017;
(5) the transaction of any other business that may properly come before the meeting or any adjournment thereof. Pursuant to the Company’s bylaws, no other items of business are expected to be considered at the meeting and no other director nominees will be entertained.
|
| 2016-11-04 |
股东大会：
将于2016-12-15召开股东大会
会议内容 ▼▲
- 1. Election of directors. Directors are elected by a plurality, with the five nominees obtaining the most votes being elected. Because there is no minimum vote required, abstentions and broker non-votes will be entirely excluded from the vote and will have no effect on its outcome. Under the plurality vote standard, any shares that are not voted, whether by abstention, broker non-votes or otherwise, will not affect the election of directors.
2. Ratification of independent registered public accounting firm. This proposal must be approved by a majority of the votes cast on the matter affirmatively or negatively. As a result, abstentions and broker non-votes will be entirely excluded from the vote and will have no effect on its outcome.
3. Advisory (non-binding) vote to approve executive compensation. This proposal will be approved if it receives the affirmative vote of a majority of the votes cast on the matter affirmatively or negatively. As a result, abstentions and broker non-votes will be entirely excluded from the vote and will have no effect on its outcome.
4. Approval of an increase in the number of shares available for issuance under the RXi Pharmaceuticals Corporation Employee Stock Purchase Plan. This proposal must be approved by a majority of the votes cast on the matter affirmatively or negatively. As a result, abstentions and broker non-votes will be entirely excluded from the vote and will have no effect on its outcome.
5. Approval of an increase in the number of shares available for issuance under the 2012 RXi Pharmaceuticals Corporation Long Term Incentive Plan. This proposal must be approved by a majority of the votes cast on the matter affirmatively or negatively. As a result, abstentions and broker non-votes will be entirely excluded from the vote and will have no effect on its outcome.
|
| 2016-04-15 |
详情>>
拆分方案：
每10.0000合并分成1.0000股
|
| 2016-03-07 |
股东大会：
将于2016-04-14召开股东大会
会议内容 ▼▲
- (1) an amendment to the Company’s Amended and Restated Certificate of Incorporation, as amended (as amended from time to time, the “Charter”), to effect a reverse stock split of the shares of the Company’s common stock, par value $0.0001 per share (the “common stock”), at a ratio of not less than 1-for-2 and not greater than 1-for-40, with the exact ratio and effective time of the reverse stock split to be determined by the Board of Directors (the “Reverse Stock Split”);
(2) to authorize the adjournment of the Special Meeting, if necessary or appropriate, if a quorum is present, to solicit additional proxies if there are insufficient votes at the Special Meeting in favor of the Reverse Stock Split;
(3) the transaction of any other business that may properly come before the Special Meeting or any adjournment or postponement thereof.
|